Hepatitis B: Competitive Landscape to 2027

Market: Pharmaceuticals

Global, 49 pages report, published by GlobalData

Report ThumbnailMay-2019
Hepatitis B: Competitive Landscape to 2027

Summary

Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 mi

Read More
  • Table of Contents
  • 1 Preface
  • 1.1 Table of Contents
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports
  • 2 Executive Summary
  • 2.1 Key Findings
  • 2.2 Key Events
  • 3 Introduction
  • 3.1 Report Scope
  • 3.2 Disease Overview and Epidemiology
  • 4 Pipeline Assessment
  • 4.1 Pipeline Overview
  • 4.2 Pipeline Breakdown by Region/Country
  • 4.3 Pipeline Breakdown by Molecule Type and Target
  • 4.4 Drug Review Designations
  • 4.5 Products in Clinical Development
  • 5 Clinical Trial Assessment
  • 5.1 Clinical Trials Overview
  • 5.
Read More

Please select a license type

Share

Related Products

GlobalDataHepatitis B: Competitive Landscape to 2027 Product ThumbnailHepatitis B: Competitive Landscape to 2027 , Industry ReportProduct #: 1201873
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2021 Global Market Analyst. All Rights Reserved